Regulatory agencies (such as UNOS, CAP, ASHI, and CLIA) require that a prospective crossmatch test be performed using a serum sample not less than 14 days old prior to the scheduled transplant. The lymphocyte crossmatch assesses the level of circulating antibodies in the potential recipient that are directed against HLA Class I and/or Class II molecules of the donor.
Interpretive report provided.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
Days Test Performed
Monday - Thursday, 8:00am - 4:30pm; Friday 8:00am - 10:30am
Soft Order Code
Cross-match Patient Serum
Kidney Transplant, Final Crossmatch
HLA Crossmatch Flow
Flow Crossmatch, Recipient
Living Final Pre-Txp, Recip
HLA Antibody Specificity Class I
HLA Antibody Specificity Class II
Looking to Order a Test?
We’ve provided helpful links to make ordering easy.
All specimens should be accompanied by a requisition.
Learn about how to properly label and where to ship specimens.
MLabs provides all the supplies necessary for the collection of specimens.
Visit our provider FAQ and learn about common questions to ordering tests.
Required: "Solid Organ TXP, Donor Cross-match Cell" must be placed on donor.
The Flow Crossmatch uses indirect immunofluorescence to detect human alloantibodies bound to target lymphocytes. IgG antibodies appear to be most associated with rejection; therefore a fluorophore cojugated anti human IgG reagent is used to detect the alloantibody binding. A second and third fluorescent parameter is used to delineate the desired cell population (T or B cell). Interpretation of the Flow Crossmatch is done by comparing the fluorescence intensity of the donor’s cells mixed with the patient's serum to the fluorescence intensity of the same donor when mixed with a known negative control serum. This fluorescent value is then converted mathematically into Median Channel Shift (MCS) or Molecules of Equivalent Soluble Fluorochrome (MESF). The final pre-transplant flow crossmatch is evaluated along with the patient’s current antibody screening results and reviewed for concordance.